Your browser doesn't support javascript.
loading
Dephosphorylation of YB-1 is Required for Nuclear Localisation During G2 Phase of the Cell Cycle.
Mehta, Sunali; McKinney, Cushla; Algie, Michael; Verma, Chandra S; Kannan, Srinivasaraghavan; Harfoot, Rhodri; Bartolec, Tara K; Bhatia, Puja; Fisher, Alistair J; Gould, Maree L; Parker, Kim; Cesare, Anthony J; Cunliffe, Heather E; Cohen, Scott B; Kleffmann, Torsten; Braithwaite, Antony W; Woolley, Adele G.
Afiliação
  • Mehta S; Department of Pathology, University of Otago, PO Box 56, Dunedin 9016, New Zealand.
  • McKinney C; Maurice Wilkins Centre for Biodiscovery, University of Otago, Dunedin 9016, New Zealand.
  • Algie M; Department of Pathology, University of Otago, PO Box 56, Dunedin 9016, New Zealand.
  • Verma CS; Department of Pathology, University of Otago, PO Box 56, Dunedin 9016, New Zealand.
  • Kannan S; Centre for Protein Research, Department of Biochemistry, University of Otago, PO Box 56, Dunedin 9016, New Zealand.
  • Harfoot R; Bioinformatics Institute (A*STAR), 30 Biopolis Street, 07-01 Matrix, Singapore 138671, Singapore.
  • Bartolec TK; School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore.
  • Bhatia P; Department of Biological Sciences, National University of Singapore, 16 Science Drive 4, Singapore 117558, Singapore.
  • Fisher AJ; Bioinformatics Institute (A*STAR), 30 Biopolis Street, 07-01 Matrix, Singapore 138671, Singapore.
  • Gould ML; Department of Pathology, University of Otago, PO Box 56, Dunedin 9016, New Zealand.
  • Parker K; Children's Medical Research Institute, University of Sydney, NSW 2145, Australia.
  • Cesare AJ; Department of Pathology, University of Otago, PO Box 56, Dunedin 9016, New Zealand.
  • Cunliffe HE; Department of Pathology, University of Otago, PO Box 56, Dunedin 9016, New Zealand.
  • Cohen SB; Department of Pathology, University of Otago, PO Box 56, Dunedin 9016, New Zealand.
  • Kleffmann T; Department of Pathology, University of Otago, PO Box 56, Dunedin 9016, New Zealand.
  • Braithwaite AW; Children's Medical Research Institute, University of Sydney, NSW 2145, Australia.
  • Woolley AG; Department of Pathology, University of Otago, PO Box 56, Dunedin 9016, New Zealand.
Cancers (Basel) ; 12(2)2020 Jan 29.
Article em En | MEDLINE | ID: mdl-32013098
ABSTRACT
Elevated levels of nuclear Y-box binding protein 1 (YB-1) are linked to poor prognosis in cancer. It has been proposed that entry into the nucleus requires specific proteasomal cleavage. However, evidence for cleavage is contradictory and high YB-1 levels are prognostic regardless of cellular location. Here, using confocal microscopy and mass spectrometry, we find no evidence of specific proteolytic cleavage. Doxorubicin treatment, and the resultant G2 arrest, leads to a significant increase in the number of cells where YB-1 is not found in the cytoplasm, suggesting that its cellular localisation is variable during the cell cycle. Live cell imaging reveals that the location of YB1 is linked to progression through the cell cycle. Primarily perinuclear during G1 and S phases, YB-1 enters the nucleus as cells transition through late G2/M and exits at the completion of mitosis. Atomistic modelling and molecular dynamics simulations show that dephosphorylation of YB1 at serine residues 102, 165 and 176 increases the accessibility of the nuclear localisation signal (NLS). We propose that this conformational change facilitates nuclear entry during late G2/M. Thus, the phosphorylation status of YB1 determines its cellular location.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article